Treatment Efficacy, Chemoradiotherapy Benefits, and Survival Disparities by Histology in Primary Mediastinal Germ Cell Tumors: 15‐Year Results of a Single‐Center Cohort Study
Asia-Pacific Journal of Clinical Oncology · 2026
DOI: 10.1111/ajco.70073 ↗Kurz gefasst
Kohortenstudie in der Zeitschrift Asia-Pacific Journal of Clinical Oncology, 2026. Verfasst von Di Wu und 15 weiteren Autor:innen. Beteiligte Einrichtung: Department of Thoracic Oncology II, Key Laboratory of Carcinogenesis and Translational Research (Ministry of Education/Beijing), Peking University Ca…. Hauptthemen laut MEDLINE: Mediastinal Neoplasms, Neoplasms, Germ Cell and Embryonal, Chemoradiotherapy. Die Arbeit nennt 33 Literaturangaben. Gefördert von: Ethics Committee of Peking University Cancer Hospital.
Abstract (Originalsprache)
Aim
Primary mediastinal germ cell tumors (PMGCTs), a rare subset of extragonadal GCTs, exhibit heterogeneous prognoses depending on histological subtype. Limited prospective clinical studies exist due to their rarity. This study analyzed therapeutic efficacy and prognostic factors for PMGCT patients.
Methods
We retrospectively analyzed PMGCT patients treated at Peking University Cancer Hospital (2009–2024). Progression‐free survival (PFS) and overall survival (OS) were evaluated using Kaplan‐Meier curves and log‐rank tests. Cox regression identified prognostic factors.
Results
Among 37 patients (the median age: 30; 35 males and two females), nine had seminomas, and 28 had non‐seminomas. All patients received chemotherapy, 21 received mediastinal radiotherapy, and 10 underwent surgery. The 1‐, 2‐, 3‐, and 5‐year OS rates were 92%, 81%, 73%, and 73%, respectively. The median PFS for the first‐line treatment (84% received bleomycin, etoposide, and cisplatin [BEP] regimen) was 9.1 months (95% confidence interval [CI] 4.6–13.5). Seminoma patients showed superior outcomes vs. non‐seminoma: PFS (not reached [NR] vs. 4.2 months, p < 0.001) and OS (NR vs. 29.5 months, p = 0.008). In non‐seminoma patients, demonstrated significant tumor reduction post‐first‐line therapy correlated with prolonged PFS ( p < 0.001). Cox regression indicated non‐seminoma patients who received mediastinal radiotherapy had significantly longer OS (hazard ratio [HR] 5.943, 95% CI 1.077–32.791; p = 0.041).
Conclusions
The BEP regimen, which was effective in testicular GCTs, demonstrates activity in PMGCTs. Seminomas showed superior therapeutic effect and survival compared to non‐seminomas. For non‐seminomas, the first‐line response might predict PFS, and mediastinal radiotherapy might provide additional survival benefits. These findings highlight histology‐driven prognostic stratification for PMGCTs and multimodal management for primary mediastinal non‐seminoma GCTs.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Autor:innen und Institutionen
- Department of Thoracic Oncology II, Key Laboratory of Carcinogenesis and Translational Research (Ministry of Education/Beijing), Peking University Cancer Hospital & Institute, Beijing, China.
- Department of Radiation Oncology, Second Affiliated Hospital, Zhejiang University School of Medicine, Hangzhou, China.
- Department of Thoracic Oncology I, Key Laboratory of Carcinogenesis and Translational Research (Ministry of Education/Beijing), Peking University Cancer Hospital & Institute, Beijing, China.
Förderung
- Ethics Committee of Peking University Cancer Hospital
Zitieren
APA
Wu, D., Zhang, Z., Nie, J., Hu, W., Dai, L., Zhang, J., Chen, X., Ma, X., Tian, G., Han, S., Han, J., Long, J., Zhang, P., Wang, L., Chen, H., & Fang, J. (2026). Treatment Efficacy, Chemoradiotherapy Benefits, and Survival Disparities by Histology in Primary Mediastinal Germ Cell Tumors: 15‐Year Results of a Single‐Center Cohort Study. Asia-Pacific Journal of Clinical Oncology. https://doi.org/10.1111/ajco.70073
Vancouver
Wu D, Zhang Z, Nie J, Hu W, Dai L, Zhang J, et al. Treatment Efficacy, Chemoradiotherapy Benefits, and Survival Disparities by Histology in Primary Mediastinal Germ Cell Tumors: 15‐Year Results of a Single‐Center Cohort Study. Asia-Pacific Journal of Clinical Oncology. 2026. doi:10.1111/ajco.70073
BibTeX
@article{Wu2026,
author = {Wu, Di and Zhang, Ziran and Nie, Jun and Hu, Weiheng and Dai, Ling and Zhang, Jie and Chen, Xiaoling and Ma, Xiangjuan and Tian, Guangming and Han, Sen and Han, Jindi and Long, Jieran and Zhang, Panpan and Wang, Lu and Chen, Hanxiao and Fang, Jian},
title = {Treatment Efficacy, Chemoradiotherapy Benefits, and Survival Disparities by Histology in Primary Mediastinal Germ Cell Tumors: 15‐Year Results of a Single‐Center Cohort Study},
journal = {Asia-Pacific Journal of Clinical Oncology},
year = {2026},
doi = {10.1111/ajco.70073}
}
EUVIMED